Quarterly ResultMay 13, 2026, 04:02 PM
Equillium Q1 Net Loss $(5.3)M; Cash Funds Ops into 2029; CDO Appointed
AI Summary
Equillium reported a reduced net loss of $5.3 million for Q1 2026, down from $8.7 million in Q1 2025, driven by lower R&D and G&A expenses. The company also announced the appointment of Snehal Naik, Ph.D., as Chief Development Officer to lead clinical development and medical strategy. Equillium is on track to initiate a Phase 1 study for EQ504 in mid-2026, with data expected six months later, and its cash and cash equivalents of $61.3 million are expected to fund operations into 2029.
Key Highlights
- Net loss for Q1 2026 was $(5.3) million, down from $(8.7) million in Q1 2025.
- Net loss per share was $(0.06) for Q1 2026, compared to $(0.24) in Q1 2025.
- R&D expenses decreased to $3.0 million in Q1 2026 from $5.9 million in Q1 2025.
- G&A expenses decreased to $2.6 million in Q1 2026 from $2.9 million in Q1 2025.
- Cash and cash equivalents totaled $61.3 million as of March 31, 2026.
- Cash and cash equivalents are expected to fund operations into 2029.
- Snehal Naik, Ph.D., appointed Chief Development Officer.
- Phase 1 study of EQ504 on track to initiate in mid-2026, with data expected six months thereafter.